Previous Close | 33.68 |
Open | 33.72 |
Bid | 32.86 x 50000 |
Ask | 34.00 x 50000 |
Day's Range | 32.83 - 33.72 |
52 Week Range | 30.62 - 38.40 |
Volume | |
Avg. Volume | 9 |
Market Cap | 17.267B |
Beta (5Y Monthly) | -0.05 |
PE Ratio (TTM) | 32.19 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 0.48 (1.46%) |
Ex-Dividend Date | Sept 27, 2024 |
1y Target Est | N/A |
Today, Ajinomoto Co., Inc. ("Ajinomoto Co.") (TSE: 2802) launched a new version of its StemFit™ iPSC expansion medium. The enhanced version of its widely used StemFit™ products is designed to improve the growth and pluripotency of induced pluripotent stem cells (iPSC) and meet the Good Manufacturing Practice (GMP) standards for Active Pharmaceutical Ingredients (API).
COLUMBUS, Ohio, November 13, 2023--Ajinomoto Co., Inc. ("Ajinomoto Co."; TYO: 2802) and Forge Biologics (Forge), announced today that they have entered into a definitive agreement by which Ajinomoto Co., will acquire Forge, a leading manufacturer of genetic medicines, in an all-cash deal for $620 million1.